0.69
+0.0463(+7.23%)
Currency In USD
| Previous Close | 0.64 |
| Open | 0.64 |
| Day High | 0.69 |
| Day Low | 0.63 |
| 52-Week High | 2.53 |
| 52-Week Low | 0.24 |
| Volume | 782,829 |
| Average Volume | 1.02M |
| Market Cap | 40.32M |
| PE | -0.62 |
| EPS | -1.1 |
| Moving Average 50 Days | 0.69 |
| Moving Average 200 Days | 0.47 |
| Change | 0.05 |
If you invested $1000 in BioAtla, Inc. (BCAB) since IPO date, it would be worth $22.13 as of November 10, 2025 at a share price of $0.687. Whereas If you bought $1000 worth of BioAtla, Inc. (BCAB) shares 3 years ago, it would be worth $84.35 as of November 10, 2025 at a share price of $0.687.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
GlobeNewswire Inc.
Nov 05, 2025 1:00 PM GMT
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, toda
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
GlobeNewswire Inc.
Oct 23, 2025 12:00 PM GMT
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, toda